This is a hybrid single-group clinical trial that will last 12 weeks. Participants will take 2 capsules daily with the first meal of the day in the morning. Participants will undertake blood tests at Baseline and Week 12. Study-specific questionnaires will be completed at Baseline, Week 4, Week 8, and Week 12. Cognitive Battery Testing will take place at Baseline, Week 4, Week 8, and Week 12.

Inclusion Criteria:

• Female at birth.
• Aged 18+.
• Interested in supporting their health and wellbeing.
• Not planning to introduce or change prescription medications, vitamins, minerals, or supplements one month prior to and during the study.
• Generally healthy with no uncontrolled chronic conditions.

Exclusion Criteria:

• Recent surgeries or invasive treatments.
• Introduction of new health-related products in the last 12 weeks.
• Allergies to product ingredients or use of Epi-Pen.
• Chronic health conditions affecting participation.
• Endocrine or glucose-related disorders, including diabetes.
• Hematological disorders, including anemia.
• Pregnant, breastfeeding, or planning to conceive.
• History of substance abuse or recent smoking.
• Unwillingness to follow the study protocol.
• Participation in other clinical trials.

This is an open-label study where no masking will be implemented.